The American Society of Clinical Oncology (ASCO) first published an endorsement of the Cancer Care Ontario guideline on the role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer in July 2016. The goal of the update of the 2016 ASCO endorsement of the Cancer Care Ontario recommendations5 is to provide oncologists and other clinicians with a summary of this evidence and revised recommendations for practice based on the data. 

For our patients with hormone receptor-positive, human epidermal growth factor receptor 2–negative, early-stage breast cancer, there are now validated tools that can help oncologists provide more individualized treatment recommendations. Recently published data from two large randomized clinical trials examining Oncotype DX and MammaPrint assays (Agendia, Irvine, CA) have yielded important evidence for use in discussions about potential benefit from chemotherapy in specific patient populations. When using the Oncotype DX assay, chemotherapy is not recommended for patients older than age 50 whose tumors have recurrence scores less than 26. For those patients younger than 50 years of age whose tumors have recurrence scores less than 16, there is little to no benefit from chemotherapy; but for those with recurrence scores of 16 to 25, clinicians may offer chemoendocrine therapy. 

So the given data is enough to show what exact role we are talking of when we say Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage Breast Cancer.

https://ascopubs.org/doi/full/10.1200/JOP.19.00266

Author